ArticleFrontiers in aging neuroscience2026
Systems-level molecular and immunological evidence identifies Th17/Treg modulation as a key mechanism of CRSJ's neuroprotection in Parkinson's disease.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder in which neuroinflammation plays a central role. Congrong Shujing Granules (CRSJ), a traditional Chinese medicine formula, have shown clinical benefits in PD, yet their immunomodulatory mechanisms remain unclear. Methods: We investigated the effects of CRSJ on Th17/Treg immune balance. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to identify representative chemical constituents of CRSJ. Representative CRSJ compounds were characterized, and their binding affinities were evaluated by molecular docking and molecular dynamics simulations. An MPTP-induced PD mouse model was established and treated with CRSJ. Behavioral outcomes, dopaminergic neuroprotection, immune cell subsets, transcriptomic profiles, and cytokine networks were assessed using flow cytometry, RNA sequencing, multiplex assays, immunofluorescence, and Western blotting. Results: HPLC analysis identified 44 representative compounds in CRSJ spanning multiple chemical classes associated with immunomodulatory, neuroprotective, and antioxidant activities. Molecular-level prioritization of CRSJ-derived serum constituents highlighted paeoniflorin as a key Th17/Treg balance immunoregulatory candidate, exhibiting stable interactions with RORγt, Foxp3, and α-synuclein in molecular docking and molecular dynamics simulations. In an MPTP-induced Parkinson's disease mouse model, CRSJ treatment dose-dependently improved motor performance, preserved dopaminergic neurons, and reduced striatal α-synuclein accumulation. Transcriptomic profiling revealed CRSJ-associated shifts toward regulatory immune programs, characterized by attenuation of Th17-related signatures and enhancement of Treg-associated pathways, accompanied by consistent modulation of the TGF-β/SMAD3 signaling axis. These molecular changes were supported by protein-level validation. CRSJ further alleviated neuroinflammation by promoting microglial M1/M2 polarization and partially normalizing dysregulated cytokine and chemokine profiles. Integrated immunological analyses demonstrated restoration of Th17/Treg balance and suppression of CX3CL1/CX3CR1-Th17 signaling, collectively supporting an immuno-neuroprotective profile of CRSJ in PD. Conclusion: CRSJ exerts neuroprotective effects in PD by restoring Th17/Treg homeostasis and suppressing neuroinflammatory pathways, supporting its potential as an immunomodulatory therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.